Business
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and
About this update from In8bio, Inc.
[{"type":"text","content":"Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling gamma-delta CAR-T platform (nsCAR) utilizing the validated target of CD19 as proof-of-concept. Leveraging the unique properties of gamma-delta T cells supports the potential to broaden the utilization of CAR technology for previously “undruggable” solid- and liquid-tumor targets. NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, announced the ability of its novel non-signaling gamma-delta CAR-T platform (nsCAR) to selectively target leukemic cells while preserving healthy B cells. The findings were presented by Dr. Lawrence Lamb, IN8bio’s Chief Scientific Officer, during a Plenary session titled \"Leveraging the Nexus of the Immune System with Gamma-Delta CAR-T Cells\" at the 6th CAR-TCR Summit Europe on February 23rd.The current generation of CAR-T technology eliminates the target antigen regardless of whether it is expressed on tumor or healthy tissues. However, IN8bio's nsCAR platform uses the innate immune recognition of gamma-delta T cells to distinguish between tumor and healthy tissue, offering a targeted but potentially less toxic approach. In a 48-hour in vitro cytotoxicity experiment, the nsCAR platform demonstrated a greater than 15x difference in killing between leukemic cells and healthy B cells (E:T=2:1, 79.7% versus 5.2%) when both express the CD19 target antigen.The nsCAR platform is also engineered to express the cytokine interleukin-15 (IL-15) to enhance cellular persistence and the ability to target and kill tumor cells over time. The platform has the potential to broaden the utilization of CAR technology for previously \"undruggable\" solid and liquid tumor targets.\"This powerful approach could be used in indications such as acute myeloid leukemia (AML) and solid tumor cancers where on-target, off-tumor expression would result in toxicities with significant risks to patients,\" said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. \"While CD19 was a preclinical proof-of-concept, we look forward to advancing the nsCAR platform into solid tumor indications as well as ...